Nuvectra (NVTR) Stock Rating Upgraded by BidaskClub
Nuvectra (NASDAQ:NVTR) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.
Several other equities analysts have also issued reports on the company. ValuEngine raised Nuvectra from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Zacks Investment Research lowered Nuvectra from a “buy” rating to a “hold” rating in a research note on Wednesday, August 29th. SunTrust Banks boosted their price target on Nuvectra to $27.00 and gave the company a “buy” rating in a research note on Thursday, June 21st. JMP Securities boosted their price target on Nuvectra from $18.00 to $23.00 and gave the company a “market outperform” rating in a research note on Wednesday, August 8th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $21.00 price target on shares of Nuvectra in a research note on Wednesday, August 8th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $23.50.
Shares of NVTR opened at $22.27 on Thursday. Nuvectra has a 52-week low of $7.60 and a 52-week high of $23.79. The company has a current ratio of 4.10, a quick ratio of 3.77 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $322.57 million, a price-to-earnings ratio of -5.28 and a beta of -1.76.
In other Nuvectra news, President Joseph Paul Hanchin sold 1,250 shares of the business’s stock in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $20.43, for a total value of $25,537.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.60% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of NVTR. Wells Fargo & Company MN raised its position in shares of Nuvectra by 97.1% during the first quarter. Wells Fargo & Company MN now owns 251,629 shares of the company’s stock worth $3,276,000 after purchasing an additional 123,964 shares during the period. JPMorgan Chase & Co. raised its position in shares of Nuvectra by 1,053.5% during the first quarter. JPMorgan Chase & Co. now owns 19,309 shares of the company’s stock worth $251,000 after purchasing an additional 17,635 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Nuvectra during the first quarter worth approximately $2,700,000. Tibra Equities Europe Ltd acquired a new position in shares of Nuvectra during the first quarter worth approximately $400,000. Finally, Next Century Growth Investors LLC acquired a new position in shares of Nuvectra during the first quarter worth approximately $1,871,000. 73.95% of the stock is currently owned by institutional investors.
Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs.
Featured Story: Do Tariffs Work?
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.